ReviewInfection2026
Chikungunya virus: global epidemiology, transmission dynamics, and emerging challenges for public health.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resurgence of Chikungunya in Thailand.IJID regions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last twenty years, Chikungunya virus (CHIKV), an arthropod-borne alphavirus, has resurged globally and emerged as an important public health concern. Driven by viral adaptive mutations, rapid urbanization, climate change, and the global expansion of Aedes mosquito habitats, CHIKV has continuously expanded its geographic distribution and triggered recurrent outbreaks across multiple continents. In this review, we comprehensively synthesize recent progress in virology, epidemiology, vector biology, diagnostic innovations, and vaccine research, emphasizing the integrated mechanisms that support its continued worldwide spread. Available data suggest that variation in vector competence, viral evolutionary adaptations (e.g., the E1-A226V mutation), and climatic-ecological shifts are key determinants of CHIKV transmission dynamics. Despite the approval of two vaccines, questions persist concerning their long-term safety profile, sustained immunogenicity, economic viability, and fair access in low-resource regions. Furthermore, substantial clinical overlap with dengue and Zika virus infections poses challenges to accurate diagnosis and epidemiological surveillance. It is essential to reinforce genomic and comprehensive vector surveillance and to develop cross-disciplinary risk prediction platforms within a "One Health" framework to improve global preparedness and response capacity. The establishment of data-informed, cooperative prevention strategies remains crucial for reducing the worldwide burden of CHIKV and other comparable arboviral diseases.
Indexed as
Identifiers
41945227What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.